10-Q: Neuraxis Reports Q1 2026 Results, Revenue Surges 79.5%

Neuraxis, Inc. announced its first quarter 2026 financial results, showcasing a significant 79.5% year-over-year increase in net sales driven by expanded insurance coverage for its IB-Stim device.

Summary

• Neuraxis, Inc. reported a net sales increase of 79.5% to $1.61 million for the first quarter ended March 31, 2026, compared to $895,655 in the same period of 2025.
• Gross profit rose by 83.8% to $1.39 million, with gross margin improving to 86.4% from 84.4%.
• Operating loss decreased by 24.2% to $1.74 million, and net loss improved by 22.7% to $1.76 million.
• The company's cash position increased to $7.08 million, with a working capital surplus of $5.33 million.
• Despite improvements, the company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong revenue growth and improved operational efficiency, but tempered by ongoing net losses and substantial doubt about the company's going concern status.

Positives

• Net sales increased significantly by 79.5% to $1,607,883 in Q1 2026, driven by expanded insurance coverage for the IB-Stim device.
• Gross profit increased by 83.8% to $1,389,517.
• Gross margin improved to 86.4% from 84.4% due to higher growth from fully reimbursed customers.
• Operating loss improved by 24.2% to $1,740,679.
• Net loss improved by 22.7% to $1,761,432.
• Cash and cash equivalents increased to $7,078,659.
• Working capital surplus increased to $5,328,867.
• Proceeds from the issuance of common stock and exercise of warrants provided significant financing.

Negatives

• The company continues to incur operating losses, with a net loss of $1,761,432 for the quarter.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• Selling expenses increased by 64.8% to $824,336 due to higher sales volume and increased personnel.
• The company has identified material weaknesses in its internal control over financial reporting, including ineffective approval processes, inadequate contract management, and misapplication of U.S. GAAP.
• Remediation efforts for internal control weaknesses are ongoing and expected to continue through fiscal year 2026.

Risks

• The company's ability to continue as a going concern is dependent on its ability to implement its business plan, generate sufficient revenues, and raise additional funds through public or private offerings.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial reporting.
• The company is subject to risks associated with the development, manufacturing, and marketing of its medical neuromodulation devices.
• Future capital requirements are significant and depend on various factors including product development, regulatory approvals, and market adoption.
• The company faces risks related to the adoption of insurance coverage by commercial insurance carriers nationally, which is crucial for revenue generation.
• Dr. Arturo Taca has asserted an interest in U.S. Patent No. 10,413,719, valued at $2,000,000, which the company denies.
• The company is involved in ongoing litigation with business entities related to prior litigation, with remaining claims pending.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it pursues widespread insurance coverage for its IB-Stim and RED devices and seeks FDA clearance for other indications. Profitability is dependent on achieving adequate revenue levels and potentially securing additional financing.

Management Comments

• Our mission is to advance drug-free neuromodulation therapies that improve patient outcomes and reduce medication burden in complex disorders, while expanding access to effective care for populations with significant unmet needs.
• Although we had stockholders equity of $5,747,550 as of March 31, 2026, our auditors have expressed substantial doubt about our ability to continue as a going concern.
• We expect to incur significant expenses and operating losses for the foreseeable future as we continue to pursue widespread insurance coverage of our IB-Stim and RED devices and seek FDA clearance of our device for other indications.
• The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial insurance carriers nationally, which is a top priority of the Company.
• Our management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements, especially that of Section 404 of the Sarbanes-Oxley Act. This additional corporate governance time required of management could limit the amount of time our management has to implement our business plan and may delay our anticipated growth plans.

Industry Context

StockSavvy.ai notes that Neuraxis's Q1 2026 results reflect a positive trend in revenue growth, largely attributed to the increasing adoption of its IB-Stim device, bolstered by a Category I CPT code and broader insurance coverage. This aligns with a broader industry trend towards non-pharmacological treatments for chronic pain and neurological conditions, where companies are seeking to demonstrate clinical efficacy and secure favorable reimbursement to drive market penetration.

Comparison to Industry Standards

• Neuraxis's gross margin of 86.4% is notably high, suggesting efficient cost management in its manufacturing and sales processes. This figure is generally above the average for many medical device companies, which often face higher COGS due to complex supply chains and regulatory compliance.
• The company's net sales growth of 79.5% is substantial, indicating strong market traction for its specific niche. While many medical device companies aim for double-digit growth, achieving nearly 80% growth in a quarter is exceptional and suggests successful market penetration or expansion of indications.
• The continued net loss, despite revenue growth, is common for growth-stage medical device companies investing heavily in R&D, sales, and marketing to achieve market adoption and regulatory approvals. This is a standard characteristic of companies in this sector, where profitability is often a longer-term goal.
• The auditor's 'going concern' note is a critical point. While not unique to Neuraxis, it highlights the financial challenges many early-stage medical device companies face in balancing rapid growth with sustainable profitability and cash flow management. Companies like Inspire Medical Systems (INSP) or Axonics (AXNX) have navigated similar phases, often requiring significant follow-on funding rounds.

Corporate Governance

Legal Proceedings

• A lawsuit initiated by Ritu Bhambhani, M.D. and Sudhir Rao was dismissed by the Court, and their subsequent appeal was denied by the Fourth Circuit.
• A separate lawsuit initiated by business entities owned or partially owned by the original plaintiffs is ongoing, with claims related to the RICO Act dismissed, but other claims pending.
• A settlement of $750,000 for the business entities lawsuit is being paid in 12 equal monthly installments, with remaining payments of $562,500 as of March 31, 2026.
• Dr. Arturo Taca has asserted an interest in U.S. Patent No. 10,413,719, valued at $2,000,000, which the company denies. This case remains unresolved.

Related Party Transactions

• Two demand notes receivable from shareholders totaling $1,012,800 principal balance, with a fully reserved allowance for collection risk.
• Loans payable to shareholders related to funding needs for operations, with a balance of $66,648 for 'Other Convertibles' at 5.0% interest.
• The Company has an exclusive license for certain patents from an LLC in which the CEO and Chief Regulatory Officer have an ownership interest. The Company is obligated to reimburse patent maintenance costs up to $20,000 for 2026.
• A Board member purchases NeuroStim devices at cost for research and development, with a pre-approved limit of $20,000 for 2026.

Stakeholder Impact

• Shareholders: The company's ongoing losses and going concern issues present significant risk. However, the revenue growth and potential for future profitability could be positive.
• Employees: Stock-based compensation and employee stock purchase plans are in place. The company's financial stability directly impacts job security.
• Customers (Healthcare Providers): Continued product adoption and insurance coverage are critical for their utilization of the IB-Stim and RED devices.
• Creditors: The company's ability to service its debt obligations is a concern given the going concern issues.

Next Steps

• Continue pursuing widespread insurance coverage for IB-Stim and RED devices.
• Seek FDA clearance for additional indications for its devices.
• Continue remediation efforts for identified material weaknesses in internal controls, expected to continue through fiscal year 2026.
• Management will focus on policies and procedures to ensure compliance with regulatory requirements, including Section 404 of the Sarbanes-Oxley Act.

Key Dates

Recommendation

Neuraxis demonstrates strong revenue growth and operational improvements, which is positive. However, the persistent net losses, the auditor's going concern warning, and material weaknesses in internal controls present significant risks that warrant a cautious 'hold' stance until these issues are demonstrably resolved and a clear path to profitability is established.

Keywords

Neuraxis, 10-Q, Quarterly Report, Medical Devices, Neuromodulation, IB-Stim, Functional Abdominal Pain, IBS, Functional Dyspepsia, Revenue Growth, Net Loss, Going Concern, Internal Controls, SEC Filing